The RIQAS Maternal Screening EQA programme is designed to monitor the performance of screening tests used during the first and second trimester of pregnancy to assess the risk of Down's syndrome, Spina Bifida and Trisomy 18.
Lyophilised material for enhanced stability

Submit results and view reports online via RIQAS.Net
Worlds largest EQA scheme ensuring peer groups are maximised
Monthly reporting for earlier identification of test system errors
Cycle Starts - January 2026
Accredited to ISO/IEC 17043:2023
To find out more about RIQAS EQA or to get in touch with your local Randox Representative, enquire now.
| Description | Frequency | Size | Cat No | |
|---|---|---|---|---|
| Maternal Screening | Monthly | 12 x 1 ml | RQ9137 |
Immunoassay
Immunoassay Speciality 1
Anti-Müllerian Hormone (AMH)